Tibolone

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H341511

CAS#: 5630-53-5

Description: Tibolone is a biochemical.

Chemical Structure

img
Tibolone
CAS# 5630-53-5
Instruction

Theoretical Analysis

Hodoodo Cat#: H341511
Name: Tibolone
CAS#: 5630-53-5
Chemical Formula: C21H28O2
Exact Mass: 312.21
Molecular Weight: 312.453
Elemental Analysis: C, 80.73; H, 9.03; O, 10.24

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Tibolone ; Xyvion; Tibolonum.

IUPAC/Chemical Name: 19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)-

InChi Key: WZDGZWOAQTVYBX-JNHCMHTRSA-N

InChi Code: InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21-/m1/s1

SMILES Code: C#C[C@@]1(O)CC[C@@]2([H])[C@]3([H])[C@H](C)CC4=C(CCC(C4)=O)[C@@]3([H])CC[C@]12C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 312.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kulkarni J, Gavrilidis E, Thomas N, Hudaib AR, Worsley R, Thew C, Bleeker C, Gurvich C. Tibolone improves depression in women through the menopause transition: A double-blind randomized controlled trial of adjunctive tibolone. J Affect Disord. 2018 Apr 24;236:88-92. doi: 10.1016/j.jad.2018.04.103. [Epub ahead of print] PubMed PMID: 29723767.

2: Pinto-Almazan R, Segura-Uribe JJ, Soriano-Ursúa MA, Farfán-García ED, Gallardo JM, Guerra-Araiza C. Effect of tibolone pretreatment on kinases and phosphatases that regulate the expression and phosphorylation of Tau in the hippocampus of rats exposed to ozone. Neural Regen Res. 2018 Mar;13(3):440-448. doi: 10.4103/1673-5374.228726. PubMed PMID: 29623928; PubMed Central PMCID: PMC5900506.

3: Crespo-Castrillo A, Yanguas-Casás N, Arevalo MA, Azcoitia I, Barreto GE, Garcia-Segura LM. The Synthetic Steroid Tibolone Decreases Reactive Gliosis and Neuronal Death in the Cerebral Cortex of Female Mice After a Stab Wound Injury. Mol Neurobiol. 2018 Mar 26. doi: 10.1007/s12035-018-1008-x. [Epub ahead of print] PubMed PMID: 29582398.

4: Hipolito Rodrigues MA, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018 Jun;21(3):256-266. doi: 10.1080/13697137.2018.1439914. Epub 2018 Mar 9. PubMed PMID: 29521155.

5: Miller E, Zalzala MH, Abunnaja MS, Kurogi K, Sakakibara Y, Suiko M, Liu MC. Effects of Human Sulfotransferase 2A1 Genetic Polymorphisms 3 on the Sulfation of Tibolone. Eur J Drug Metab Pharmacokinet. 2018 Feb 1. doi: 10.1007/s13318-017-0458-2. [Epub ahead of print] PubMed PMID: 29392568.

6: Løkkegaard ECL, Mørch LS. Tibolone and risk of gynecological hormone sensitive cancer. Int J Cancer. 2018 Jun 15;142(12):2435-2440. doi: 10.1002/ijc.31267. Epub 2018 Feb 2. PubMed PMID: 29349823.

7: Wang K, Li F, Chen L, Lai YM, Zhang X, Li HY. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget. 2017 Aug 11;8(46):81109-81124. doi: 10.18632/oncotarget.20154. eCollection 2017 Oct 6. PubMed PMID: 29113371; PubMed Central PMCID: PMC5655266.

8: Staples L, Milder T, Choi PY. Polycythaemia Secondary to Hormone Replacement Therapy with Tibolone. Case Rep Hematol. 2017;2017:3476349. doi: 10.1155/2017/3476349. Epub 2017 Sep 27. PubMed PMID: 29090100; PubMed Central PMCID: PMC5635276.

9: Gambacciani M, Biglia N, Cagnacci A, Caruso S, Cicinelli E, DE Leo V, DI Carlo C, Farris M, Gambera A, Guaschino S, Lanzone A, Paoletti AM, Russo N, Vicariotto F, Villa P, Volpe A; Italian Menopause Society (SIM). Menopause and hormone replacement therapy: the 2017 Recommendations of the Italian Menopause Society. Minerva Ginecol. 2018 Feb;70(1):27-34. doi: 10.23736/S0026-4784.17.04151-X. Epub 2017 Oct 3. PubMed PMID: 28975776.

10: Segura-Uribe JJ, Pinto-Almazán R, Coyoy-Salgado A, Fuentes-Venado CE, Guerra-Araiza C. Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system. Neural Regen Res. 2017 Aug;12(8):1231-1240. doi: 10.4103/1673-5374.213536. Review. PubMed PMID: 28966632; PubMed Central PMCID: PMC5607812.

11: Hidalgo-Lanussa O, Ávila-Rodriguez M, Baez-Jurado E, Zamudio J, Echeverria V, Garcia-Segura LM, Barreto GE. Tibolone Reduces Oxidative Damage and Inflammation in Microglia Stimulated with Palmitic Acid through Mechanisms Involving Estrogen Receptor Beta. Mol Neurobiol. 2017 Sep 25. doi: 10.1007/s12035-017-0777-y. [Epub ahead of print] PubMed PMID: 28948468.

12: Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3647-3661. doi: 10.1210/jc.2017-01138. Review. PubMed PMID: 28934376.

13: Jung JH, Song GG, Lee YH, Kim JH, Hyun MH, Choi SJ. Serum uric acid levels and hormone therapy type: a retrospective cohort study of postmenopausal women. Menopause. 2018 Jan;25(1):77-81. doi: 10.1097/GME.0000000000000953. PubMed PMID: 28796699.

14: Bała M, Sahebkar A, Ursoniu S, Serban MC, Undas A, Mikhailidis DP, Lip GYH, Rysz J, Banach M; Lipid Blood Pressure Meta-Analysis Collaboration Group. Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. Pharmacol Res. 2017 Oct;124:64-73. doi: 10.1016/j.phrs.2017.07.024. Epub 2017 Jul 29. PubMed PMID: 28760491.

15: González-Giraldo Y, Garcia-Segura LM, Echeverria V, Barreto GE. Tibolone Preserves Mitochondrial Functionality and Cell Morphology in Astrocytic Cells Treated with Palmitic Acid. Mol Neurobiol. 2018 May;55(5):4453-4462. doi: 10.1007/s12035-017-0667-3. Epub 2017 Jun 30. PubMed PMID: 28667487.

16: Neri-Gómez T, Espinosa-Raya J, Díaz-Cintra S, Segura-Uribe J, Orozco-Suárez S, Gallardo JM, Guerra-Araiza C. Tibolone modulates neuronal plasticity through regulating Tau, GSK3β/Akt/PI3K pathway and CDK5 p35/p25 complexes in the hippocampus of aged male mice. Neural Regen Res. 2017 Apr;12(4):588-595. doi: 10.4103/1673-5374.205098. PubMed PMID: 28553339; PubMed Central PMCID: PMC5436357.

17: Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update. 2017 Jul 1;23(4):481-500. doi: 10.1093/humupd/dmx011. Review. PubMed PMID: 28498913; PubMed Central PMCID: PMC5850813.

18: Whicker M, Black J, Altwerger G, Menderes G, Feinberg J, Ratner E. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am J Obstet Gynecol. 2017 Oct;217(4):395-403. doi: 10.1016/j.ajog.2017.04.012. Epub 2017 Apr 12. Review. PubMed PMID: 28411144.

19: Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, Theodorou M, Goulis DG. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2017 May;99:27-36. doi: 10.1016/j.maturitas.2017.02.009. Epub 2017 Feb 16. Review. PubMed PMID: 28364865.

20: Pinto-Almazán R, Segura-Uribe JJ, Farfán-García ED, Guerra-Araiza C. Effects of Tibolone on the Central Nervous System: Clinical and Experimental Approaches. Biomed Res Int. 2017;2017:8630764. doi: 10.1155/2017/8630764. Epub 2017 Jan 16. Review. PubMed PMID: 28191467; PubMed Central PMCID: PMC5278195.